It is now widely recognized that atherosclerosis is an inflammatory process that proceeds through several stages of development that share common features with other forms of chronic inflammatory disease. The consequence of this inflammatory reaction is fibro-proliferative plaque formation that narrows the lumenal opening of large and medium size arteries. Many studies using genetically altered mice have confirmed that the macrophage plays a critical role in mediating the chronic inflammation characteristically seen in atherosclerotic plaques. The prevailing paradigm for atherosclerosis also implicates lipid accumulation in the artery wall, particularly in macrophages, as being critical to the initiation and development of these inflammatory events. In this grant proposal, we will generated transgenic animals whose macrophages can be ablated at various time points in the development of atherosclerotic lesions through the use of drugs that activate toxins encoding by the transgenes. These experiments are intended to explore the role of proliferating macrophages in lesion development and progression and to clarify the necessity for the continue presence of macrophages for the process of atherogenesis. The grant will also make use of homologous recombinant mice that do not express the three currently established scavenger receptor family members (SR-A (type I and type II macrophage scavenger receptors), CD36, and CD68) to determine the impact of reduced modified lipoprotein uptake on lesion development. Previous work has suggested that reduced modified lipoprotein uptake does result in smaller atherosclerotic plaques in the hyperlipidemic mouse models of the disease, but no single scavenger receptor can account for more than half of the lipid ingested. By generating animals deficient in all three scavenger receptor family members, it is anticipated that this work will be able to determine the significance of foam cell formation and lipid activation of macrophages via these receptor pathways on lesion development. These studies should provide valuable insights into the role of macrophage receptors in atherogenesis that could serve as the basis for new therapeutic strategies to treat coronary heart disease and its complications.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL045098-10
Application #
6351468
Study Section
Metabolism Study Section (MET)
Program Officer
Applebaum-Bowden, Deborah
Project Start
1990-07-01
Project End
2004-01-31
Budget Start
2001-02-01
Budget End
2002-01-31
Support Year
10
Fiscal Year
2001
Total Cost
$422,731
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Manning-Tobin, Jennifer J; Moore, Kathryn J; Seimon, Tracie A et al. (2009) Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler Thromb Vasc Biol 29:19-26
Moore, Kathryn J; Freeman, Mason W (2008) Targeting Innate Immunity for CV Benefit. Drug Discov Today Ther Strateg 5:15-23
Fitzgerald, Michael L; Xavier, Ramnik; Haley, Kathleen J et al. (2007) ABCA3 inactivation in mice causes respiratory failure, loss of pulmonary surfactant, and depletion of lung phosphatidylglycerol. J Lipid Res 48:621-32
Moore, Kathryn J; Kunjathoor, Vidya V; Koehn, Stephanie L et al. (2005) Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest 115:2192-201
Kim, Woojin Scott; Fitzgerald, Michael L; Kang, Kihwa et al. (2005) Abca7 null mice retain normal macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels. J Biol Chem 280:3989-95
Okuhira, Kei-ichiro; Fitzgerald, Michael L; Sarracino, David A et al. (2005) Purification of ATP-binding cassette transporter A1 and associated binding proteins reveals the importance of beta1-syntrophin in cholesterol efflux. J Biol Chem 280:39653-64
Bjorkbacka, Harry; Fitzgerald, Katherine A; Huet, Francois et al. (2004) The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol Genomics 19:319-30
Fitzgerald, Michael L; Okuhira, Kei-Ichiro; Short 3rd, Glenn F et al. (2004) ATP-binding cassette transporter A1 contains a novel C-terminal VFVNFA motif that is required for its cholesterol efflux and ApoA-I binding activities. J Biol Chem 279:48477-85
Bjorkbacka, Harry; Kunjathoor, Vidya V; Moore, Kathryn J et al. (2004) Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 10:416-21
El Khoury, Joseph B; Moore, Kathryn J; Means, Terry K et al. (2003) CD36 mediates the innate host response to beta-amyloid. J Exp Med 197:1657-66

Showing the most recent 10 out of 32 publications